Ignite Creation Date:
2024-05-06 @ 1:48 PM
Last Modification Date:
2024-10-26 @ 1:20 PM
Study NCT ID:
NCT04124965
Status:
COMPLETED
Last Update Posted:
2023-09-05
First Post:
2019-10-11
Brief Title:
A Study to Investigate the Long-term Safety Tolerability and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Randomized Open-Label Extension Study to Investigate the Long-Term Safety Tolerability and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the MycarinGstudy is to evaluate the long-term safety tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis MG
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-000969-21 | EUDRACT_NUMBER | None | None |